Physician profile
Prince Paul
NPI 1073746012
$1,748.86
in general payments reported to CMS, 2019-2025
14 companies · $813 in 2025
The $813 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $199 · 2022: $125 · 2023: $52.80 · 2024: $559 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,175 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.80 |
| Education | $249.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $510.69 | 2022-2025 | Cresemba, Xospata |
| Incyte Corporation | $289.90 | 2021-2025 | Jakafi, Monjuvi |
| Sanofi-Aventis U.S. LLC | $261.39 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $166.86 | 2025 | |
| Ucb, INC. | $100.04 | 2024 | Nayzilam |
| Janssen Biotech, INC. | $96.32 | 2025 | Darzalex, Tecvayli, Talvey |
| Celgene Corporation | $78.89 | 2022-2023 | Reblozyl, Onureg |
| Merck Sharp & Dohme LLC | $68.58 | 2025 | Prevymis, Zerbaxa |
| Taiho Oncology, INC. | $33.66 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.30 | 2025 | Livtencity |
| Sobi, INC | $29.30 | 2025 | |
| Invivyd INC | $28.97 | 2024 | Pemgarda |
| Abbvie INC. | $27.29 | 2024 | |
| Gamida Cell INC. | $23.67 | 2025 | Omisirge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prince Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.